Book Online or Call 1-855-SAUSALITO

Sign In  |  Register  |  About Sausalito  |  Contact Us

Sausalito, CA
September 01, 2020 1:41pm
7-Day Forecast | Traffic

  • Search Hotels in Sausalito

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

United Therapeutics Corporation - Common Stock (NQ: UTHR )

359.40 -4.70 (-1.29%)
Streaming Delayed Price Updated: 1:56 PM EST, Dec 27, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about United Therapeutics Corporation - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
7 Biotech Stocks With Key Catalysts for May
The beaten-down state of biotech stocks is a major pulling point for investors who are aiming for market-leading returns. 
Via InvestorPlace
The Daily Biotech Pulse: Kezar Life's Lead Asset Fails, Brickell Biotech Offloads Late-Stage Asset, Connect Biopharma Ulcerative Colitis Trial Disappoints
Here's a roundup of top developments in the biotech space over the last 24 hours. 
Via Benzinga
Recap: United Therapeutics Q1 Earnings
United Therapeutics (NASDAQ:UTHR) reported its Q1 earnings results on Wednesday, May 4, 2022 at 08:00 AM. Here's what investors need to know about the announcement. 
Via Benzinga
United Therapeutics Corporation Reports First Quarter 2022 Financial Results
From United Therapeutics Corporation
Via Business Wire
Earnings Scheduled For May 4, 2022
Companies Reporting Before The Bell • Seres Therapeutics (NASDAQ:MCRB) is estimated to report quarterly loss at $0.52 per share on revenue of $8.48 million. 
Via Benzinga
Earnings Outlook For United Therapeutics
United Therapeutics (NASDAQ:UTHR) is set to give its latest quarterly earnings report on Wednesday, 2022-05-04. Here's what investors need to know before the announcement. Analysts estimate that United... 
Via Benzinga
United Therapeutics Q1 2022 Earnings Conference Call On May 4, 2022 At 09:00 AM ET
United Therapeutics (NASDAQ:UTHR) will host a conference call at 09:00 AM ET on May 4, 2022, to discuss Q1 2022 earnings results. How to Attend United Therapeutics (UTHR) Conference Call Follow this... 
Via Benzinga
United Therapeutics to Feature Clinical Data Across its Commercial and Development Portfolio at the 2022 American Thoracic Society International Conference
From United Therapeutics Corporation
Via Business Wire
United Therapeutics Corporation to Report First Quarter 2022 Financial Results Before the Market Opens on Wednesday, May 4, 2022
From United Therapeutics Corporation
Via Business Wire
United Therapeutics Announces the Publication of Tyvaso DPI™ BREEZE Clinical and Long-term Data in the Journal Pulmonary Circulation
From United Therapeutics Corporation
Via Business Wire
First Human With Pig Heart Transplant Dies: Reuters
A 57-year-old man with terminal heart disease who became the first person to receive a genetically modified pig's heart has died, the University of Maryland Medical... 
Via Benzinga
10 Biggest Price Target Changes For Monday
Barclays cut the price target on MasTec, Inc. (NYSE: MTZ) from $140 to $120. MasTec shares fell 0.1% to $79.00 in pre-market trading. 
Via Benzinga
Ferrer Announces Distribution Agreement With United Therapeutics for Treprostinil Inhalation Solution for Pulmonary Hypertension Associated With Interstitial Lung Disease
PH-ILD is a rare, serious, and progressive illness without an approved treatment in Europe and many other parts of the world 
Via Newswire.com
United Therapeutics Earnings Perspective: Return On Capital Employed
Pulled from Benzinga Pro data, United Therapeutics (NASDAQ:UTHR) posted Q4 earnings of $112.20 million, an increase from Q3 of 31.04%. Sales dropped to $415.20 million, a 6.63%... 
Via Benzinga
FDA Pushes United Therapeutics-MannKind Tyvaso DPI's Decision Date; United Therapeutics' Q4 Misses Consensus
United Therapeutics Corp (NASDAQ: UTHR) and its partner MannKind Corp (NASDAQ: MNKD) have received an FDA information request letter for additional... 
Via Benzinga
United Therapeutics Corporation Reports Fourth Quarter and Full Year 2021 Financial Results
From United Therapeutics Corporation
Via Business Wire
United Therapeutics's Earnings Outlook
United Therapeutics (NASDAQ:UTHR) is set to give its latest quarterly earnings report on Thursday, 2022-02-24. Here's what investors need to know before the announcement. Analysts... 
Via Benzinga
United Therapeutics Corporation to Report Fourth Quarter and Full Year 2021 Financial Results Before the Market Opens on Thursday, February 24, 2022
From United Therapeutics Corporation
Via Business Wire
United Therapeutics Corporation Announces Historic Achievements in its Xenotransplantation Programs
From United Therapeutics Corporation
Via Business Wire
First Successful Pig Heart Transplant Into Human: Details On The Amazing Technology And A Public Company To Watch
Pigs may not be able to fly, but they've provided a vital organ in a life-saving surgery for one U.S. man. What Happened: A Maryland hospital completed the first... 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Gainers Black Diamond Therapeutic (NASDAQ:BDTX) stock increased by 18.2% to $5.32 during Tuesday's pre-market session. The market value of their outstanding shares is... 
Via Benzinga
7 Pharmaceutical Stocks That Could Make You Rich
Due to expiring patents and rising competition, successful pharmaceutical stocks need to develop robust drug pipelines. 7 Pharmaceutical Stocks That Could Make You Rich 
Via InvestorPlace
Mark To Market
I thought that I would have a look at my own financial performance in 2021. In preview, I did alright, but not as well as the market. Let's take a look at what my portfolio held and how well it did. 
Via Talk Markets
United Therapeutics Corporation to Webcast Executive Fireside Chat Conversation With J.P. Morgan Analyst
From United Therapeutics Corporation
Via Business Wire
United Therapeutics Named by Newsweek as One of America’s Most Responsible Companies 2022
From United Therapeutics Corporation
Via Business Wire
Liquidia's Inhaled Treprostinil Powder Scores Tentative FDA Approval For PAH
The FDA has granted tentative approval to Liquidia Corporation's (NASDAQ: LQDA) Yutrepia (treprostinil) inhalation powder for pulmonary arterial... 
Via Benzinga
Exposures Product Safety
United Therapeutics Corporation (UTHR) Q3 2021 Earnings Call Transcript
UTHR earnings call for the period ending September 30, 2021. 
Via The Motley Fool
Topics Earnings
Exposures Financial
The Daily Biotech Pulse: Cerus Climbs On Earnings, Horizon CFO To Retire, Teva Prices Upsized Sustainability-Linked Senior Note Offering
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Horizon Announces Retirement Of CFO, Beat-and-raise Q3 Horizon Therapeutics... 
Via Benzinga
Topics Retirement
Exposures Pension
Recap: United Therapeutics Q3 Earnings
United Therapeutics (NASDAQ:UTHR) reported its Q3 earnings results on Wednesday, November 3, 2021 at 08:00 AM. Here's what investors need to know about the announcement... 
Via Benzinga
Earnings Scheduled For November 3, 2021
Companies Reporting Before The Bell • R.R.Donnelley & Sons (NYSE:RRD) is likely to report quarterly earnings at $0.32 per share on revenue of $1.19 billion.... 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Photos copyright by Jay Graham Photographer
Copyright © 2010-2020 Sausalito.com & California Media Partners, LLC. All rights reserved.